New strategy for overcoming resistance to chemotherapy of ovarian cancer

Yonago Acta Medica

Volumn 56, Issue 2, 2013, Pages 43-50

  Kigawa, Junzo ^a  

^a TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemotherapy; Molecular targeted agent; Ovarian cancer; Resistance

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; FIRTECAN; GEMCITABINE; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM COMPLEX; TAXANE DERIVATIVE; VASCULOTROPIN A;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CANCER RESISTANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE 1 GENE; MULTIPLE CYCLE TREATMENT; ONCOGENE; OVARY CANCER; PERITONEUM CANCER; PREDICTION; PROTEIN TARGETING; PROTEINURIA; REVIEW; UNSPECIFIED SIDE EFFECT; UTERINE TUBE CARCINOMA;

EID: 84880175586     PISSN: 05135710     EISSN: 13468049     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Naniwa J, Itamochi H, Kigawa J. Implication of clear cell and mucinous histology [Internet]. In: Díaz-Padilla I, editor. Ovarian cancer a clinical and translational update. Chapter 5. New York: InTech; c2004-2013. Available from: http://wwwcancerorg/Research/CancerFactsFigures/GlobalCancerFactsFigures/global-facts-figures-2nd-ed.
2. th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecology Obstet. 2006;95 Suppl 1:S161-92. PMID: 17161157.
3. Japan Society of Gynecologic Oncology, The, editor. [Ovarian cancer treatment guideline 2010]. Tokyo: Kanehara; 2010. Japanese.
4. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts. DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-25. PMID: 19224846.
5. Williams LL. Secondary cytoreduction of ovarian malignancies. In: Markman M, Hoskins WJ, editors. Cancer of the ovary. New York: Raven Press; 1993. p. 187-203.
6. Thigpen JT, Bertelsen K, Eisenhauer EA, Hacker NF, Lund B, Sessa C. Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol. 1993;4:35-40. PMID: 8312199.
7. Andrews PA, Velury S, Mann SC. Cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1988;48:68-73. PMID: 3335000.
8. Kigawa J, Minagawa Y, Cheng X, Terakawa N. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 1998;4:1737-41. PMID: 9676849.
9. Lautier D, Canitrot Y, Deeley RG, Cole SP. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol. 1996;52:967-77. PMID: 8831715.
10. Kigawa J, Terakawa N. Adenovirus-mediated transfer of a p53 gene in ovarian cancer. Adv Exp Med Biol. 2000;465:207-14. PMID: 10810628.
11. Minagawa Y, Kigawa J, Itamochi H, Kanamori Y, Shimada M, Takahashi M, et al. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent andindependent pathways. Jpn J Cancer Res. 1999;90:1373-9. PMID: 10665656.
12. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997;8:963-8. PMID: 9402168.
13. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-93. PMID: 1999708.
14. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 1993;71:1559-64. PMID: 8094320.
15. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1748-53. PMID: 7916038.
16. Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, et al. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res. 2003;9:4682-8. PMID: 14581337.
17. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64:1403-10. PMID: 14973057.
18. Drlica K, Franco RJ. Inhibitors of DNA topoisomerases. Biochemistry. 1988;27:2253-9. PMID: 2838070.
19. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 1989;28:4629-38. PMID: 2548584.
20. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino) 1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987;47:5944-7. PMID: 3664496.
21. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225-9. PMID: 1321891.
22. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (cpt CPT-11). Clin Cancer Res. 2001;7:2182-94. PMID: 11489791.
23. Tsuruno T, Matsuzaki T, Matsushita M, Fukuoka M, Kusunoki Y, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol. 1988;21:71-4. PMID: 3342468.
24. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer. 1992;50:604-10. PMID: 1537625.
25. Minagawa Y, Kigawa J, Irie T, Kanamori Y, Itamochi H, Cheng X, et al. Enhanced topoisomerase I activity and topoisomerase II alpha content in cisplatin-resistant cancer cell lines. Jpn J Cancer Res. 1997;88:1218-23. PMID: 9473741.
26. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 1996;56:789-93. PMID: 8631015.
27. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, et al. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res. 1997;3:1245-52. PMID: 9815806.
28. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res. 1995;55:2097-103. PMID: 7743509.
29. Kigawa J, Takahashi M, Minagawa Y, Oishi T, Sugiyama T, Yakushiji M, et al. Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin11and cisplatin in patients with ovarian cancer. Int J Cancer. 1999;84:521-4. PMID: 10502731.
30. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;22:2192-205. PMID: 12687021.
31. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, et al. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:76-82. PMID: 17291235.
32. Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, et al. Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86:171-6. PMID: 12144824.
33. Itamochi H. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biolo Chem. 2010;1:209-20. PMID: 21537476.
34. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111-37. PMID: 19278961.
35. Kigawa J. Releveance of genetic and epigenetic changes to treatment. Chemotherapeutic strategies for gynecologic cancers. In: Kikuchi Y, editor. Chemotherapeutic strategies for gynecological cancers. Kerala: Transworld Research Network; 2011. p. 5-19.
36. Kigawa J. Molecular-targeted therapy for ovarian cancer. (review) Int J Clin Oncol. 2012;17:423. PMID: 22926639.
37. Shimogai R, Kigawa J, Itamochi H, Iba T, Kanamori Y, Oishi T, et al. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer. 2008;18:499-505. PMID: 18476949.
38. Kim KJ, Bing LI Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362;841-4. PMID: 7683111.
39. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307;58-62. PMID: 15637262.
40. Micha JP, Goldsten BH, Rettenmainer MA, Genesen M, Graham C, Bader K, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17:771-6. PMID: 17343605.
41. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-83. PMID: 22204724.
42. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A Phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-96. PMID: 22204725.
43. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-45. PMID: 22529265.
44. Downward J. Cancer biology: signatures guide drug choice. Nature. 2006;19:274-5. PMID: 16421553.
45. Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res. 2006;12:2964-6. PMID: 16707590.
46. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, et al. Inhibition of phosphorylation of BAD and Raf1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277:33490-500. PMID: 12087097.
47. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, et al. Targeted inhibition of transient activation of the EGFRmediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol. 2005;27:1441-8. PMID: 16211241.
48. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2terminal kinase and Akt. Cancer Res. 2006;66:212-20. PMID: 16397234.
49. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153-64. PMID: 11832206.
50. Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, et al. Simultaneous inhibition of the mitogenactivated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer Sci. 2007;98:2002-8. PMID: 17900261.
51. Sinha D, Bannergee S, Schwartz JH, Lieberthal W, Levine JS. Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis. J Biol Chem. 2004;279:10962-72. PMID: 14701865.
52. Nonaka M, Itamochi H, Kawaguchi W, Kudoh A, Sato S, Uegaki K, et al. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. Int J Gynecol Cancer. 2012;22:922-9. PMID: 22672985.
53. Punt CJ, Mol L, Koopman M. Bevacizumab and cancer treatment-related mortality. JAMA. 2011;305:2292. PMID: 21642679.